Characterization of long-circulating cationic nanoparticle formulations consisting of a two-stage PEGylation step for the delivery of siRNA in a breast cancer tumor model

Journal of Pharmaceutical Sciences

Volumn 102, Issue 1, 2013, Pages 227-236

  Ho, Emmanuel A ^a   Osooly, Maryam ^b   Strutt, Dita ^b   Masin, Dana ^b   Yang, Youngjoo ^b   Yan, Hong ^b   Bally, Marcel ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

Biomaterials; Cancer; Cationic lipids; Liposomes; Nanoparticles; Nanotechnology; Non viral gene delivery; Pegylation; RNAi; SiRNA

Indexed keywords

CATIONIC LIPID NANOPARTICLE; LIPOSOME; LUCIFERASE; MACROGOL; MESSENGER RNA; NANOPARTICLE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CHEMICAL MODIFICATION; CIRCULATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG STABILITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PLASMA; RECEPTOR DOWN REGULATION; TUMOR LOCALIZATION; TUMOR XENOGRAFT;

EID: 84870717467     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23351     Document Type: Article

References (32)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA Cancer J Clin 61(2):69-90.
2. Whelan J. 2005. First clinical data on RNAi. Drug Discov Today 10(15):1014-1015.
3. DeVincenzo J, Cehelsky JE, Alvarez R, Elbashir S, Harborth J, Toudjarska I, Nechev L, Murugaiah V, Van Vliet A, Vaishnaw AK, Meyers R. 2008. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res 77(3):225-231.
4. Akhtar S, Hughes MD, Khan A, Bibby M, Hussain M, Nawaz Q, Double J, Sayyed P. 2000. The delivery of antisense therapeutics. Adv Drug Deliv Rev 44(1):3-21.
5. Dykxhoorn DM, Lieberman J. 2005. The silent revolution: RNA interference as basic biology, research tool, and therapeutic. Annu Rev Med 56:401-423.
6. Dykxhoorn DM, Lieberman J. 2006. Knocking down disease with siRNAs. Cell 126(2):231-235.
7. Watanabe TA, Geary RS, Levin AA. 2006. Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleot 16(2):169-180.
8. Bradley AJ, Devine DV, Ansell SM, Janzen J, Brooks DE. 1998. Inhibition of liposome-induced complement activation by incorporated poly(ethylene glycol)-lipids. Arch Biochem Biophys 357(2):185-194.
9. Ho EA, Ramsay E, Ginj M, Anantha M, Bregman I, Sy J, Woo J, Osooly-Talesh M, Yapp DT, Bally MB. 2010. Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties. J Pharm Sci 99(6):2839-2853.
10. Phillips WT, Klipper RW, Awasthi VD, Rudolph AS, Cliff R, Kwasiborski V, Goins BA. 1999. Polyethylene glycol-modified liposome-encapsulated hemoglobin: A long circulating red cell substitute. J Pharmacol Exp Ther 288(2):665-670.
11. Fenske DB, Palmer LR, Chen T, Wong KF, Cullis PR. 2001. Cationic poly(ethyleneglycol) lipids incorporated into pre-formed vesicles enhance binding and uptake to BHK cells. Biochim Biophys Acta 1512(2):259-272.
12. Hope M, Bally M, Webb G, Cullis P. 1985. Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta 812:55-65.
13. Qian M, Chen SH, von Hofe E, Gallo JM. 1997. Pharmacokinetics and tissue distribution of a DNA-methyltransferase antisense (MT-AS) oligonucleotide and its catabolites in tumor-bearing nude mice. J Pharmacol Exp Ther 282(2):663-670.
14. Xu H, Rice BW. 2009. In-vivo fluorescence imaging with a multivariate curve resolution spectral unmixing technique. J Biomed Opt 14(6):064011.
15. Brodbeck KJ, Profio AE, Frewin T, Balchum OJ. 1987. A system for real time fluorescence imaging in color for tumor diagnosis. Med Phys 14(4):637-639.
16. Tateishi K, Ando W, Higuchi C, Hart DA, Hashimoto J, Nakata K, Yoshikawa H, Nakamura N. 2008. Comparison of human serum with fetal bovine serum for expansion and differentiation of human synovial MSC: Potential feasibility for clinical applications. Cell Transplant 17(5):549-557.
17. Foged C, Nielsen HM, Frokjaer S. 2007. Liposomes for phospholipase A2 triggered siRNA release: Preparation and in vitro test. Int J Pharm 331(2):160-166.
18. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, Jadhav V, Vaish N, Zinnen S, Vargeese C, Bowman K, Shaffer CS, Jeffs LB, Judge A, MacLachlan I, Polisky B. 2005. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23(8):1002-1007.
19. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. 1990. Direct gene transfer into mouse muscle in vivo. Science 247(4949 Pt 1):1465-1468.
20. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M. 1987. Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 84(21):7413-7417.
21. Hofland HE, Shephard L, Sullivan SM. 1996. Formation of stable cationic lipid/DNA complexes for gene transfer. Proc Natl Acad Sci USA 93(14):7305-7309.
22. Tousignant JD, Gates AL, Ingram LA, Johnson CL, Nietupski JB, Cheng SH, Eastman SJ, Scheule RK. 2000. Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice. Hum Gene Ther 11(18):2493-2513.
23. Litzinger DC, Brown JM, Wala I, Kaufman SA, Van GY, Farrell CL, Collins D. 1996. Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim Biophys Acta 1281(2):139-149.
24. Santel A, Aleku M, Keil O, Endruschat J, Esche V, Fisch G, Dames S, Loffler K, Fechtner M, Arnold W, Giese K, Klippel A, Kaufmann J. 2006. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Therapy 13(16):1222-1234.
25. Li CL, Cui JX, Wang CX, Zhang L, Li YH, Xiu X, Li YF, Wei N. 2010. Development of pegylated liposomal vinorelbine formulation using "post-insertion" technology. Int J Pharm 391(1-2):230-236.
26. Giatrellis S, Nounesis G. 2011. Nucleic acid-lipid membrane interactions studied by DSC. J Pharm Bioallied Sci 3(1):70-76.
27. Allen C, Dos Santos N, Gallagher R, Chiu GN, Shu Y, Li WM, Johnstone SA, Janoff AS, Mayer LD, Webb MS, Bally MB. 2002. Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci Rep 22(2):225-250.
28. Chiu GN, Bally MB, Mayer LD. 2001. Selective protein interactions with phosphatidylserine containing liposomes alter the steric stabilization properties of poly(ethylene glycol). Biochim Biophys Acta 1510(1-2):56-69.
29. Edwards K, Johnsson M, Karlsson G, Silvander M. 1997. Effect of polyethyleneglycol-phospholipids on aggregate structure in preparations of small unilamellar liposomes. Biophys J 73(1):258-266.
30. Fenske DB, Palmer LR, Chen T, Wong KF, Cullis PR. 2001. Cationic poly(ethyleneglycol) lipids incorporated into pre-formed vesicles enhance binding and uptake to BHK cells. Biochim Biophys Acta 1512(2):259-272.
31. Hristova K, Kenworthy A, McIntosh TJ. 1995. Effect of bilayer composition on the phase behavior of liposomal suspensions containing poly(ethylene glycol)-lipids. Macromolecules 28(23):7693-7699.
32. Boussif O, Zanta MA, Behr JP. 1996. Optimized galenics improve in vitro gene transfer with cationic molecules up to 1000-fold. Gene therapy 3(12):1074-1080.